Piper Sandler reiterates CRISPR Therapeutics stock rating at overweight
Piper Sandler maintained an Overweight rating and $110 price target for CRISPR Therapeutics (CRSP) after positive clinical data presentations. CTX310 showed significant reductions in lipid parameters, while zugo-cel demonstrated high response rates in various diseases. CRSP reported Q3 2026 sales of $99M for CASGEVY and holds $2.36B in cash. Analysts have mixed views on its valuation and price targets.
How this was made
The 30-second read
Why it matters
The reiteration of Overweight and a $110 target reflect confidence in the pipeline, likely prompting buying interest.
Market read
New clinical data and analyst upgrade provide fresh catalyst for CRSP, making it a near‑term trade idea.
What to watch
Potential regulatory hurdles for CTX310 and the need for larger Phase II trials may temper enthusiasm.
Background
The article reports analyst coverage changes and summarizes recent early‑stage trial data for CRISPR Therapeutics' lipid‑lowering program and autoimmune candidates.
Ticker impact
Piper Sandler reiterated an Overweight rating and $110 price target for CRISPR Therapeutics after fresh Phase I/II clinical data presentations at major medical meetings.
likely upward pressure as market prices in the new clinical data and higher target.
The rating change and $110 target are new, directly tied to the disclosed trial results, which are material for a biotech.
Market effects
Positive data may lift other gene‑editing and lipid‑therapy biotech stocks.
US biotech sector could see modest gains in early trading.
Limited to investors focused on CRISPR and related biotech themes.
Counterpoint
If later‑stage data fail to confirm early results, the stock could face a sharp correction.
Key entities
- analystPiper Sandler
Equity research firm that upgraded CRISPR Therapeutics.
- companyCRISPR Therapeutics
Biotech developing CTX310 and zugo‑cel programs.
